MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 14, 2007; DOI: 10.1124/mol.107.036566


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.036566v1
72/5/1289    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by He, F.
Right arrow Articles by Song, Z.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by He, F.
Right arrow Articles by Song, Z.-H.


Received for publication March 29, 2007.
Revised August 13, 2007.
Accepted for publication August 14, 2007.

INVOLVEMENT OF HSP-90 IN CB2 CANNABINOID RECEPTOR-MEDIATED CELL MIGRATION ----A NEW ROLE OF HSP-90 IN MIGRATION SIGNALING OF A G PROTEIN-COUPLED RECEPTOR

Fang He 1, Zhuan-Hong Qiao 1, Jian Cai 1, William Pierce 1, Da-Cheng He 2, Zhao-Hui Song 1*

1 University of Louisville 2 Beijing Normal University

* Address correspondence to: E-mail: zhsong{at}louisville.edu

Abstract

The endocannabinoid 2-arachidonoylglycerol (2-AG) enhances cell migration through the CB2 receptor. In this study, using an immunoprecipitation and mass spectrometry based proteomic approach; we first identified Hsp90, a chaperone protein with novel signaling functions, as a CB2 interacting protein. The CB2/Hsp90 interaction was confirmed in HEK293 cells expressing transfected CB2 and in differentiated HL-60 cells expressing endogenous CB2, by co-immunoprecipitation and western-blot experiments, as well as by treatment with geldanamycin (GA), a specific Hsp90 inhibitor. Disruption of the CB2/Hsp90 interaction by treatment with GA or reducing Hsp90 levels with specific short interfering RNAs markedly inhibited 2-AG-induced cell migration, demonstrating that Hsp90 is crucial for 2-AG-induced cell migration. 2-AG treatment resulted in a CB2-mediated stimulation of Rac1 activity, and treatment with GA blocked 2AG-induced activation of Rac1. Importantly, expression of the dominant negative form of Rac1 reduced 2-AG-induced cell migration. These data demonstrate that 2-AG-induced activation of Rac1 activity is essential for 2-AG-induced cell migration, and the CB2/Hsp90 interaction is needed for 2-AG-induced activation of Rac1. Furthermore, 2-AG-induced Rac1 activation was sensitive to pertussis toxin treatment, hence involving Gi proteins. In addition, treatment with GA significantly inhibited the CB2/G{alpha}i2 interaction. Collectively, our data indicate that Hsp90 serves as scaffold to keep the CB2 receptor and its signaling components, including G{alpha}i2, in close proximity, thus facilitating CB2-mediated signaling to cell migration through the Gi-Rac1 pathway. By demonstrating that Hsp90 is essential for CB2-mediated signaling to cell migration, this study reveals a novel role of Hsp90 in the signaling events mediated by a G protein-coupled receptor.


Key words: Cannabinoid, Cdc42, rho, rac, other small G proteins





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics